Table 1.
Parameters used in the study, children < 5 years
| EPIDEMIOLOGICAL PARAMETERS, CHILDREN | Source1 | |
|---|---|---|
| Malaria attributable fevers (MAF)/febrile patients (dry season) | 3.18% | Primary |
| Malaria attributable fevers (MAF)/febrile patients (rainy season) | 63.05% | Primary |
| Malaria parasite density > 40,000/μL (both seasons) | 37.6% | Primary |
| Malaria parasite density ≤40,000/μL (both seasons) | 62.4% | Primary |
| Death rate treated MAF, high parasite density | 0.60% | Primary |
| Excess death rate untreated MAF, high parasite density | 9.4% | Assumption |
| Excess death rate untreated MAF low parasite density | 0.25% | Assumption |
| Excess death rate untreated MAF in RDT neg | 0.1% | Assumption |
| Death rate treated NMFI | 0.84% | Primary |
| Proportion of potentially fatal non malarial fever (PFNM) | 20% | Assumption |
| Excess death rate untreated PFNM | 7% | Assumption |
| CASE MANAGEMENT, PRESUMPTIVE BRANCH, CHILDREN | ||
| Anti-malarial treatment among MAF | 94.1% | Primary |
| Anti-malarial treatment among MAF, high parasite density | 100% | Primary |
| Anti-malarial treatment among MAF, low parasite density | 87% | Assumption |
| Anti-malarial treatment among those treated with antibiotics | 86.3% | Primary |
| Anti-malarial treatment among those not treated with antibiotics | 97.4% | Primary |
| Antibiotic treatment among NMFI | 64.5% | Primary |
| Antibiotic treatment among PFMN | 90% | Assumption |
| Antibiotic treatment among patients presumptively treated for malaria | 54.4% | Primary |
| Antibiotic treatment among PFMN presumptively treated for malaria | 76% | Assumption |
| Antibiotic treatment among patients not presumptively treated for malaria | 89.7% | Primary |
| Antibiotic treatment among PFMN not treated for malaria | 100% | Assumption |
| CASE MANAGEMENT, RDT, CHILDREN | ||
| Anti-malarial treatment among RDT+, high parasite density (hpd) | 100% | Primary |
| Anti-malarial treatment among RDT+, low parasite density (lpd) | 98.1% | Primary |
| Anti-malarial treatment among RDT- | 10.0% | Assumption2 |
| Antibiotic treatment among RDT+ | 52.9% | Primary |
| Antibiotic treatment among PFNM RDT+ | 76% | Assumption |
| Antibiotic treatment among RDT- | 86.1% | Assumption2 |
| Antibiotic treatment among PFNM RDT- | 98% | Assumption |
| RDT ACCURACY, CHILDREN | ||
| RDT sensitivity, malaria attributable fever (MAF), lpd, dry season | 95% | Primary |
| RDT specificity, malaria attributable fever (MAF), dry season | 71% | Primary |
| RDT sensitivity, malaria attributable fever (MAF), lpd, rainy season | 95.9% | Primary |
| RDT specificity, malaria attributable fever (MAF), rainy season | 36.7% | Primary |
| RDT sensitivity, MAF, high parasite density | 100% | Primary |
| COSTS, CHILDREN | ||
| Cost of RDT | 0.71 | Ref. 26 |
| Cost of anti-malarial treatment, Coartem (average, €) | 1 | Ref. 26 |
| Cost of antibiotic treatment (average, €) | 0.5 | Estimate |
| Life Value (€) corresponding to 25 US $*YLL | 525 | (see text) |
| Life Value (€) corresponding to 150 US $*YLL | 3150 | (see text) |
1 Primary data obtained from previous RCT (Ref. 15) and from previous assessment of the RDT accuracy (Ref. 14); assumptions based on estimates from primary data, expert opinion and previous literature (see explanation in text).
2 Assuming "ideal" 90% adherence to the negative test result (see explanation in text).